If you are not happy with the results below please do another search
Billionaire investor Icahn, who owns 1.4% of Illumina, launched a proxy battle against the company earlier this month seeking divestment of cancer test developer Grail as the $7.1 billion acquisition cost investors billions of dollars.
The gene therapy has yet to be approved in the U.S. PTC expects to submit a Biologics License Application (BLA) to the FDA in the first half of 2023, the company announced.
In a double data drop yesterday, AbbVie touted two clinical trial wins. Topline data from the Phase III INSPIRE study showed Skyrizi (risankizumab) met its primary and all secondary endpoints in ulcerative colitis and Rinvoq (upadacitinib) aced its Phase II SLEek trial, showing therapeutic potential in systemic lupus erythematosus.
The company said the focus of its drug research would shift away from women’s health, a traditional pillar of Germany’s largest drugmaker, to hone in on neurology, rare diseases and immunology.
Despite positive results Monday from a Phase III trial of KarXT (xanomeline-trospium) and analysts’ recommendations to buy, Karuna Therapeutics’ stock dropped more than 19% in 48 hours this week.
The accelerated approval pathway is commonly used for approval of oncology drugs in part due to the serious and life-threatening nature of cancer and because of available intermediate clinical endpoints likely to predict clinical benefit.
A California judge’s decision to allow expert testimony linking GSK’s heartburn drug Zantac to cancer wasn’t a surprise, analysts said, though the litigation will likely weigh on the drugmaker’s share price until a trial in the summer.
David joins CultHealth with close to 15 years of diverse marketing and creative experience in life sciences and has been closely involved with blockbuster launches, startup acceleration, productization, the genomics revolution, and the advent of connected care.
Industry innovators and change leaders Neil Matheson, John ‘Zeke’ Czekanski, and Scott Roberts have joined forces under the CiTRUS Health Group umbrella to create a robust, boutique strategic consulting business that blends Scientific & Medical Communications with Market Access.
One of the COVID pandemic’s many far-reaching ripple-effects on the healthcare industry is the accelerated adoption of virtual healthcare. Virtual patient care is shaking up our health ecosystem, and it’s forcing our entire industry to re-think the customer journey. Jay Appel discusses a few of the best communication strategies, alternative channels, and messaging adjustments that ad agencies can deploy to help pharma companies support the virtual customer experience – for patients and healthcare professionals.